Jan 31 | News
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the FDA has approved JentaduetoT (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin.
|
Jan 6 | News
FORMA Therapeutics has entered into a research and development collaboration with Boehringer Ingelheim to discover and develop novel drug candidates for the treatment of cancer.
|
Nov 15 2011 | News
RIDGEFIELD, Conn. (AP) — Boehringer Ingelheim is building a $65 million research and development center at its western Connecticut site.
|
Oct 20 2011 | News
Patheon, Inc., a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that Boehringer Ingelheim, a leading globally operating pharmaceutical corporation, has awarded it two projects with combined revenue of more than $18 million over a three year period of time.
|
Oct 11 2011 | News
Boehringer Ingelheim Pharmaceuticals, Inc. recently announced that the FDA approved COMBIVENT RESPIMAT, a new, propellant-free inhaler product that uses a slow-moving mist to deliver the same active ingredients of COMBIVENT Inhalation Aerosol in a metered dose inhaler (COMBIVENT MDI). COMBIVENT RESPIMAT will be available for patients in mid-2012.
|
Oct 6 2011 | News
FOSTER CITY, Calif. (AP) — Gilead Sciences Inc. said Wednesday that it has obtained the global rights to develop and bring to market an HIV treatment from German pharmaceutical company Boehringer Ingelheim.
|
Aug 4 2011 | News
The European
Commission (EC) today approved Boehringer Ingelheim's breakthrough oral
anticoagulant, Pradaxa(R) (dabigatran etexilate) for the prevention of stroke
in patients with atrial fibrillation (AF) at risk of stroke.
|
Jul 24 2011 | News
Ingelheim, Germany, 26 May 2011 – Over one million votes received for projects submitted as part of a global initiative mark the success and worldwide reach of a campaign, initiated by Boehringer Ingelheim, to raise awareness for stroke prevention in atrial fibrillation (AF). The...
|
May 12 2011 | News
Ingelheim, Germany, 12 May 2011 – The Fédération Équestre Internationale (FEI) has now included the Non Steroidal Anti- Inflammatory Drug (NSAID) Metacam® (meloxicam), a Boehringer Ingelheim medicine for the relief of pain and inflammation, on its "List of...
|
May 4 2011 | News
Ingelheim, Germany and Indianapolis, IN, 3 May 2011- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved linagliptin tablets, a prescription medication used along with diet and exercise to lower blood...
|